Jeff Collins to sit on the review panel for the Life Science Company Showcase Event at the North Carolina Biotechnology Center in Research Triangle Park, NC
Methylgene announces the initiation of a Phase 2 trial of MGCD0103
MethylGene Inc. (TSX: MYG) announced today the initiation of a Phase II clinical trial (Trial 013) evaluating MGCD0103, an isoform-selective histone deacetylase (HDAC) inhibitor product candidate, in combination with Vidaza(R) (azacitidine for injection), a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).
Jeff Collins was elected to a 3-year term on the Board of Directors of NCBIO at its annual meeting, in Winston-Salem, NC
NCBIO elected four new members to the organization’s Board of Directors and re-elected six other individuals at the annual meeting in Winston-Salem, May 19th. Jeff Collins, Executive in Residence, Pappas Ventures; Norris Tolson, President and CEO of the NC Biotechnology Center; Susan Thomason, Executive Director Global Business Development, NovaQuest; and Jan Turek, President and CEO of Biolex Therapeutics will serve until 2011.
